Tata India Pharma & HealthCare Fund

April 23, 2026

RA Jainee

Tata India Pharma & Healthcare Fund

Fund at a Glance
NAV Growth (Rs.)	34.78
NAV Bonus (Rs.)	—
NAV IDCW (Rs.)	34.78
Min. Investment (Rs.)	5,000
Min. SIP Investment (Rs.)	100
Min. No of Cheques	6
Benchmark	BSE Healthcare TRI
AUM Rs.	1,229 Cr
	(As on 31-Mar-2026)
Expense	0.72%
1 Year Return (%)	2.51
3 Year Return (%)	23.31
5 Year Return (%)	14.79
10 Year Return (%)	13.70
Return Since Launch	12.83%

⚖️ Sahifund Review – Tata India Pharma & Healthcare Fund ✔

PLUS: Stability, track record, cost efficiency

MINUS: Large AUM, large-cap bias, momentum lag

Sahifund View (Decisive Line):
X

👉 Apply Online | Ask Us MF Queries |

| NFO Guidance |

Tata Mutual Fund

What lies ahead? Below we decode returns consistency, portfolio concentration, peer positioning and risk profile in detail.

Suitable For Which Investors?
Nobody should invest in Pharma funds in our opinion, because:
• They have a narrow focus on only pharmaceutical and healthcare companies
• Instead, diversified equity funds which invest across sectors are better
If you still choose to invest:
1. Invest only through SIP
2. Have a 7+ year investment horizon
3. Be prepared to withstand interim sharp declines in investment value

Fund’s Investment Strategy:
The scheme seeks long term capital appreciation by investing atleast 80% of it’s net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.

Fund Manager:

1) Rajat Srivastava
Education: Mr. Srivastava has done BBA (Banking & Insurance), PGDM – IMT Ghaziabad
Experience: Prior to joining Tata Mutual Fund, he has worked with Incred Asset Management, Kotak Investment Banking, Emkay Global, Evalueserve and Motilal Oswal Financial Services

Investment Details

Min. Investment (Rs)	5,000
Min. Addl Investment (Rs)	1,000
Min. SIP Investment (Rs)	100
Min. Withdrawal (Rs)	500
Min. No of Cheques	6
Min. Balance (Rs)	500
Lock-in Period	NA
Exit Load	0.25% for redemption within 30 days

Basic Details of Tata India Pharma & Healthcare Fund

Fund House	Tata Mutual Fund
Launch Date	28-Dec-15
Return Since Launch	12.83%
Benchmark	BSE Healthcare TRI
Riskometer	Very High
Type	Open-ended
Assets	1,229 Cr
	(As on 31-Mar-2026)
Expense	0.72%
	(As on 31-Mar-2026)
Risk Grade	Above Average
Return Grade	Average
Turnover	94.20%

Tata India Pharma and Healthcare Fund Returns

Fund name	YTD	1D	1M	3M	6M	1Y	3Y	5Y	7Y	10Y
Tata India Pharma & Healthcare Dir	-1.66	0.18	3.30	2.31	-4.16	2.51	23.31	14.79	20.05	13.70
BSE Healthcare TRI	-0.55	0.11	2.81	4.17	-4.10	3.42	24.64	13.86	17.98	11.49
Equity: Sectoral-Pharma	0.44	0.27	3.49	4.42	-1.71	5.59	23.20	14.49	20.68	13.94
Rank within category	21	17	13	20	19	18	6	4	5	2
Number of funds in category	24	25	25	24	23	21	12	10	8	4

Peer Comparison of Tata India Pharma and Healthcare Fund

	Rating	1 Year Returns	3 Year Returns	5 Year Returns	Expense Ratio (%)	Net Assets (Rs Cr)	Return Since Launch (%)	Exit Load (Days)	Fund Age	Turnover (%)
Tata India Pharma & Healthcare Dir	3 star	2.51	23.31	14.79	0.72	1,229	12.83	0.25 (30)	10Y 3M	94.20
ICICI Pru Pharma Healthcare and Diagnostics Dir	5 star	5.22	26.97	16.58	1.05	6,293	20.23	1.00 (15)	7Y 9M	57.00
SBI Healthcare Opportunities Dir	4 star	4.16	25.57	16.62	0.92	4,064	17.21	0.50 (15)	13Y 3M	25.00
UTI Healthcare Dir	4 star	6.55	25.32	14.73	1.30	1,056	15.50	1.00 (30)	13Y 3M	33.00
Nippon India Pharma Dir	3 star	3.04	22.62	14.08	0.93	7,898	17.04	1.00 (30)	13Y 3M	14.00